Compare MLM & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | ALNY |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 38.9B |
| IPO Year | 1996 | 2004 |
| Metric | MLM | ALNY |
|---|---|---|
| Price | $549.58 | $274.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 28 |
| Target Price | ★ $689.36 | $471.00 |
| AVG Volume (30 Days) | 615.0K | ★ 1.5M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | ★ 25.06 | 2.33 |
| Revenue | ★ $6,150,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $13.76 | $52.67 |
| Revenue Next Year | $7.98 | $31.48 |
| P/E Ratio | ★ $22.44 | $114.46 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $525.38 | $266.53 |
| 52 Week High | $710.97 | $495.55 |
| Indicator | MLM | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 38.82 |
| Support Level | $525.38 | N/A |
| Resistance Level | $633.80 | $318.35 |
| Average True Range (ATR) | 15.76 | 16.37 |
| MACD | -4.05 | -3.96 |
| Stochastic Oscillator | 0.21 | 6.57 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.